INTRODUCTION
The disparity between the occurrence of Helicobacter pylori infection and the expression of clinically significant disease, 'the African enigma', has led some to postulate that this bacterium does not play a major role in the aetiology of upper gastrointestinal pathology in developing countries. Some have gone so far as to suggest that there is no established correlation between the organism and any pathology in Africa apart from gastritis, 1, 2 and, indeed, that infection with the organism in Africa may be protective against inter alia gastric cancer. 3 The 'evidence' for these views is derived largely from sero-epidemiological studies in asymptomatic individuals combined with anecdotal evidence about HELICOBACTER PYLORI IN AFRICA absence', we have attempted to take a fresh look at the relationship between H. pylori infection and gastroduodenal pathology in the African setting, using a retrospective literature survey of all the data (both serological and mucosal) published on the organism in Africa, as well as endoscopically controlled studies on gastroduodenal pathology. Analysis of these data provide a current summary of the available data relating to the prevalence of the infection and the occurrence of gastroduodenal disease in the African setting.
METHODS
A literature review was conducted by using a Medline search for the years 1981-97. The name of the country and Helicobacter (Campylobacter) pylori was used to generate search strings. An additional search of the primary literature, which revealed additional references, was also conducted. Manuscripts as well as abstracts and letters supplying endoscopic data were included in the final analysis if absolute numbers were provided. Duplicate communications were excluded. The literature was divided into sero-epidemiological studies and studies which involved upper gastrointestinal endoscopy with the aim of evaluating both H. pylori status and the presence of gastroduodenal pathology with special reference to peptic ulcer disease and gastric cancer. All studies were included for completeness. The information derived from appropriate studies is grouped in tabular form for ease of reading. Tables 2-4 were constructed such that actual numbers are indicated where available, the percentages are bracketed and the prevalence of H. pylori (and percentage) is included. The inherent fallibility in determining incidence and prevalence rates, often from studies whose primary aims were different (some studies focused on peptic ulceration, 7-9 while others focused on cancer 10, 11 ), is acknowledged.
Statistical analysis
The Fisher test for comparing dichotomous samples was used to examine the relationship between H. pylori and gastric pathologies for each distinct country.
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RESULTS
A total of eight sero-epidemiological studies with information about four countries were available for study. These studies evaluated immunoglobulin (Ig)G antibodies against H. pylori in either children or adults by using commercial or modified commercial ELISA kits. There were 24 endoscopically based studies comprising 14 countries available for analysis of associated pathology: 11 studies for referrals of either dyspepsia or epigastric pain lasting longer than 2 weeks, seven prospective studies investigating the relationship between the organism and the disease in a similar study group, one retrospective study and five studies of consecutive endoscopies for the organism in symptomatic subjects. One to two biopsies were available from the antrum in 23 cases and one biopsy was available from the fundus in two cases. Histology (Giemsa, Warthin-Starry stain) was available in 21 studies, the organism was cultured in seven and urease activity was measured in four studies.
Sero-epidemiology of Helicobacter pylori
We separated the sero-epidemiological studies into prevalences for different age groups in order to question some of the assumptions about the natural history of H. pylori infection. The early age of acquisition of H. pylori IgG antibodies in African children is demonstrated by seropositivity rates of 41% (seven of 17) in 0-1-year-old South Africans, 12 13.5% in 3 months-2-year-old South African children from Bloemfontein 13 and 57% (12/21) in Nigerian children of 6 months-2 years.
14 Overall, antibodies were present in 317/635 (50%) of children under 10 years of age (Table 1) . Analysis suggested that significantly more children were infected in Nigeria (82%) 14 than in Algeria, Cote d'Ivoire or Natal, South Africa (P < 0.05). The prevalence of antibodies was lowest in children from the one South African study (42%). 12 Irrespective of these differences, the presence of serum antibodies was considerably higher than generally reported for children in developed nations (< 5-10%). This review confirms both the early acquisition of antibodies against H. pylori 14,17 These discrepancies remain to be resolved but may be a reflection of the sensitivity and specificity of the serological kits used (a potential problem with all sero-epidemiological studies). 16 
Endoscopic prevalence of Helicobacter pylori in dyspeptic subjects
Helicobacter pylori was present in 72% of all dyspeptic subjects, with a range from 25 to 97%. The prevalence of H. pylori was high (60-97%) in 19 of the 21 studies cited.The prevalence in the remaining two studies, from Uganda and Sudan, was 25 and 39%, respectively. 18, 19 Despite this, this review confirms the high prevalence of the organism in the gastric mucosa in most dyspeptic populations in Africa.
Helicobacter pylori and gastritis
Helicobacter pylori is causal for chronic (antral, type B) gastritis throughout the world, including African countries. While the overall prevalence of gastritis was 60% and H. pylori 85% (Table 2) , gastritis was present in 77% of samples positive for H. pylori. These data confirm that the organism is associated with gastritis in Africa. Helicobacter pylori was also found fairly often in the fundus (40-76%), 10, 20 but there were no reports detailing the presence or extent of H. pylori-associated fundic gastritis.
The importance of gastritis as a precursor lesion has been recently demonstrated by observations of a strong relationship between gastric ulcer, gastric cancer and multifocal atrophic gastritis. 21 Unfortunately, the paucity of histological details makes it almost impossible to analyse the sequelae of H. pylori and gastritis in the studies reviewed.
Helicobacter pylori and peptic ulcer disease
Ulcer disease in Africa has reflected either one of two polarities. In central Africa, it is apparently not uncommon for surgeons to manage perforated ulcer disease. 4 In contrast, the first two cases of ulcer disease in black South African women were associated with the extremely rare Zollinger-Ellison syndrome. 22, 23 Dyspeptic symptoms, however, appear to be more consistently common in sub-Saharan Africa. In some regions they may account for up to 10% of all hospital admissions. 24 This review summates the published endoscopic and histological findings from subjects complaining of upper gastrointestinal symptomatology (dyspeptic H. pylori in Africa 853 symptoms of 2 weeks-3 months duration: epigastric pain, nausea, vomiting, heartburn, postprandial pain and bloating) referred for endoscopy in 14 African countries. The bias inherent in this is acknowledged.
Duodenal ulceration
In this review, duodenal ulceration (DU) was evident in 26% of patients with dyspepsia and H. pylori was coevident in 90% (Tables 3,4 ). Traditional areas of high DU incidence (west coast of Africa, Nile-Congo watershed) often had a high prevalence of DU, of the order of 30-59%, among patients referred for endoscopy, with some exceptions. While only 9% of cases studied in the Cote-d'Ivoire were found to have DU, a similar percentage of patients with gastric ulcers were also seen in this country. 25 Of particular interest was the finding of a high prevalence of DU in southern Africa, traditionally considered to be a low-incidence area. In a prospective study from Zimbabwe, DU was noted in 516 of 1714 patients (30%) referred for endoscopy; the authors calculated a crude prevalence rate of 456/100 000. 9 In South Africa, the prevalence of DU ranged from 12 to 30%. [26] [27] [28] All available studies to date suggest that duodenal disease is associated with H. pylori gastritis in almost every case in developed countries. 21, 29 It is postulated that gastric metaplasia (GM) in the duodenum colonized by H. pylori precedes the formation of duodenal ulcers in developed nations and that GM varies from 41 to 90% in these patients. We could only identify one study that investigated the relationship between GM and DU in the African setting. Forty-six of 64 patients (72%) with DU from Cape Town demonstrated the presence of GM, 30 suggesting a similar aetiopathogenetic mechanism for this disease process as in developed nations.
Gastric ulceration
The ratio of DU to gastric ulceration (GU) is 4:1 in developed nations. Data for GU prevalence in Africa are fragmentary: previous observations 1 have suggested a very high DU:GU ratio (in the order of 15-20:1) in African countries and in India. 31 In one South African study, examining admissions of black patients to a large teaching hospital between 1979 and 1988, the ratio of DU to GU ranged between 5:1 and 9:1. 32 In this review, albeit a collocation of studies whose main objective may not have been to determine GU prevalence, GU was identified in 7% of cases, while H. pylori infection was noted in 75% of them (Tables 3,4 ). There was a wide range in the DU:GU from 1:4 to 41:0, but on average was approximately 4:1. This spread is of interest and probably reflects the heterogeneity of the study objectives.The inherent bias in over-interpreting these results is, therefore, noted.
Helicobacter pylori and gastric cancer
Multifocal atrophic gastritis increases the risk of developing gastric carcinoma (GC) and a positive correlation exists between the prevalence of intestinal metaplasia (IM) (particularly type III) and the incidence of GC. 21, 33 In spite of the difficulties in grading atrophy, there appears to be a good correlation between atrophic gastritis and IM. In the present review, atrophic gastritis was present in 28% of cases, while IM and GC were present in 14 and 3.4% of cases, respectively ( Table 3) . The presence of H. pylori varied between 69 and 78% in these samples (Table 4 ).
In the absence of accurate population statistics in the majority of African countries, the proportional fre-
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quency of one tumour compared with that of all the others has been used as an indicator of tumour incidence. 34 Using this measure, the prevalence of GC has been noted in the past to be 2-3% of all malignancies in Nigeria, Sudan, Uganda and Zimbabwe. 1 In South Africa, in the latest publications available, GC, as a percentage of all cancers, ranges from 3.3 to 11.5% depending on ethnic grouping. 35 Non-standardized rates would seem to suggest incidences as low as 0.8 per 100 000, 3 while age-standardized rates vary from 2.4 to 20 per 100 000. 35 In the present review, the overall prevalence of GC in subjects with dyspepsia and epigastric pain was 3.4%: in western Africa it ranged from 1 to 2%, in central Africa between 2 and 7% and in South Africa it was 3%. The data suggest that both GC and its precursor lesions are not rare in African patients with dyspepsia, but the caveat of over-interpretation should be obvious.
Helicobacter pylori and intervention
The best test of a cause and effect relationship between an organism and any pathology is to evaluate the effect of eradication on disease symptomatology or recurrence. In one study in South Africa, eradication therapy in 27 patients resulted in a duodenal ulcer relapse of (7) 387 (28) 106 (14) 62 ( five patients (19%) over a 2-year period. 36 Of the two instances of re-infection in this group, one was associated with DU relapse. Of the 21 patients with 'healed' duodenal ulcers who were infected with the organism, 15 relapsed. The effect of eradication on the natural history of GU disease has been less well documented. However, in a similar study at the same institution, eradication therapy in 24 patients resulted in a GU relapse of two (8%), while 50% (eight of 16) of the noneradicated group relapsed over the 12-month study period. 37 It appears that eradication of the organism is an effective long-term treatment strategy, at least for peptic ulcer disease. Re-infection is low in Africa, despite the high prevalence of the organism. 36, 37 Although clearly limited, these data support the practice of H. pylori eradication in H. pylori-associated peptic ulcer disease (PUD) in the African setting.
DISCUSSION
The relationship between H. pylori infection and gastric pathology in Africa is controversial and many authors have suggested that the organism either has no relationship to pathology or that it has a protective effect. This state of affairs is clearly at odds with that in developed countries, despite the recent publication of differing views. 38 The difficulty with definitively ascribing a pathogenic role to H. pylori in the African setting is aggravated by the paucity of appropriate studies directly investigating this. In addition, a review of the literature reveals that the several assumptions regarding peptic ulcer incidence in sub-Saharan Africa have been based on clinical findings, X-ray evidence, surgical experience and necroscopy examinations reported 20-30 years ago. 4, 5 In spite of these difficulties, a review of the prospective, endoscopically based studies in the H. pylori era, albeit in subjects who have been selected by varying criteria which may represent a selection bias, is somewhat at odds with current perceptions. Indeed, it would appear that the organism's association with gastritis in Africa is as strong as in the rest of the world and the available data generated in the endoscopy era suggest that the infection is strongly associated with PUD, while PUD itself may not be as rare as is commonly perceived. It is of interest that the data under review show a predominance of DU disease. In this context, the observations of Hansson et al. regarding the potential for DU disease to protect against the development of gastric cancer may be relevant. 21 Clearly, prospective studies need to be performed. It should be noted that the dogma underpinning the 'African enigma' (i.e. a relative paucity of upper gastrointestinal disease in the African setting) has been questioned before. Cook stated as early as the 1980s that 'the belief strongly held earlier in this century that peptic ulcer was rare in Africans, in Africa, is now therefore firmly demolished'. 39 In recent years, several biological studies have suggested that H. pylori may influence some of the mechanisms of gastric carcinogenesis. Evidence for a link between the organism and gastric cancer has been pro-
856
vided by findings that the prevalence of infection is high in populations with a high incidence of gastric cancer; others indicate that infected individuals have an increased risk (two-12 fold) of developing gastric cancer. It should be noted, however, that none of these data were generated in sub-Saharan African countries. 40 However, a recent publication reviewing evidence for H. pylori as a cofactor in gastric cancer stresses the paucity of hard evidence in this field. 41 The authors are of the view that gastric cancer is due to a series of complex and correlated variables rather than to a single event, but concede that H. pylori probably plays an important role. There is no argument that in developed nations, atrophic gastritis increases the risk of developing GC and a positive correlation does exist between the prevalence of type III IM and the incidence of GC. 33 In H. pylori-positive patients in developed countries, the prevalence of IM ranges between 17 and 30%. 33 This review reveals that IM was present in 2-24% in the five series reported. The prevalence of H. pylori was 78% in these samples.These values are similar to those in developed nations and considerably higher than those quoted for India. 6 Unfortunately, neither gastritis nor IM were adequately graded in these African studies and it is difficult to establish the possible potential risks of these predisposing conditions. The findings of a relatively high prevalence of GC (1-7%) in these samples suggest that prospective studies are clearly needed before any firm conclusions about a mechanistic role for H. pylori in GC in Africa can be drawn.
The basis of the 'African enigma', a perceived low prevalence of H. pylori-associated diseases in the setting of a high H. pylori carrier rate, may possibly be another expression of Africa's poor medical infrastructure, as evidenced by the 'health for all indicators' of the World Health Organization's 1996 Report. 42 This report also identifies a further factor that may influence the expression of disease. It is clear that the average life expectancy in sub-Saharan Africa is much lower than in industrialized countries; the 1995 life expectancy in sub-Saharan Africa was 53 years (range . It is tempting to speculate whether an enigma exists at all or whether this phenomenon results from the difficulty inherent in determining the prevalence of a disease with a low mortality in the African setting. Our current review of available published endoscopic data suggest that well conducted, prospective collection of endoscopic data are clearly needed in order to resolve this position. The enigma may be in need of more science.
